AI assistant
ARS Pharmaceuticals, Inc. — Director's Dealing 2024
Jan 4, 2024
32159_dirs_2024-01-04_6a4bb888-3435-45b2-9ef4-5ba96777407b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ARS Pharmaceuticals, Inc. (SPRY)
CIK: 0001671858
Period of Report: 2023-05-17
Reporting Person: Tanimoto Sarina (Chief Medical Officer, 10% Owner)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-05-17 | Common Stock | G | 1050000 | $0.00 | Disposed | 3276854 | Direct |
| 2023-05-17 | Common Stock | G | 1050000 | $0.00 | Acquired | 1050000 | Indirect |
| 2023-05-17 | Common Stock | G | 1050000 | $0.00 | Disposed | 4126822 | Indirect |
| 2023-05-17 | Common Stock | G | 1050000 | $0.00 | Acquired | 2100000 | Indirect |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-01-02 | Stock option (right to buy) | $5.58 | A | 300000 | Acquired | 2034-01-01 | Common Stock (300000) | Direct |
| 2024-01-02 | Stock option (right to buy) | $5.58 | A | 880000 | Acquired | 2034-01-01 | Common Stock (880000) | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 1772850 | Indirect |
| Common Stock | 1772850 | Indirect |
Footnotes
F1: These shares are held in a trust for the benefit of the Reporting Person and her spouse. The Reporting Person and her spouse are trustees of the trust.
F2: The Form 4 filed November 10, 2022 inadvertently omitted 849,968 shares indirectly owned by the Reporting Person. The omitted shares are directly owned by the Reporting Person's spouse and were properly reported on his Form 4 filed November 10, 2022. The amount listed in Column 5 has been adjusted to reflect the correct holdings after giving effect to the May 17, 2023 gift transaction.
F3: The Reporting Person is trustee of the trust.
F4: The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F5: 25% of the shares subject to the option shall vest on January 1, 2025, and the remaining shares will vest monthly thereafter over three years.